ADVERTISEMENT

From ASCO: Updates in HER2-positive breast cancers

BY DEBU TRIPATHY
PUBLISHED WEDNESDAY, JUNE 5, 2013
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Debu Tripathy blog image

Debu Tripathy, MD, editor-in-chief of CURE, discusses preliminary studies on combining Herceptin (trastuzumab) with existing drugs to treat HER2-positive breast cancer. These highlighted studies were presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.



Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
ADVERTISEMENT
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$